Europe - Euronext Milan - BIT:REC - IT0003828271 - Common Stock
The current stock price of REC.MI is 48.26 EUR. In the past month the price increased by 0.37%. In the past year, price decreased by -12.09%.
ChartMill assigns a technical rating of 1 / 10 to REC.MI. When comparing the yearly performance of all stocks, REC.MI is a bad performer in the overall market: 85.67% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to REC.MI. While REC.MI is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months REC.MI reported a non-GAAP Earnings per Share(EPS) of 1.97. The EPS increased by 10.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.42% | ||
| ROA | 7.87% | ||
| ROE | 21.77% | ||
| Debt/Equity | 1.16 |
15 analysts have analysed REC.MI and the average price target is 60.33 EUR. This implies a price increase of 25.02% is expected in the next year compared to the current price of 48.26.
For the next year, analysts expect an EPS growth of 4.24% and a revenue growth 12.79% for REC.MI
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 10.76 | 198.69B | ||
| SAN.PA | SANOFI | 10.74 | 198.28B | ||
| 1SAN.MI | SANOFI | 10.85 | 200.25B | ||
| MRK.DE | MERCK KGAA | 15.11 | 56.04B | ||
| UNC.DE | UCB SA | 40.61 | 50.71B | ||
| UCB.BR | UCB SA | 40.42 | 50.48B | ||
| BAYN.DE | BAYER AG-REG | 7.88 | 41.35B | ||
| 1BAYN.MI | BAYER AG-REG | 7.9 | 41.45B | ||
| IPN.PA | IPSEN | 13.25 | 11.41B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 110.82 | 10.26B | ||
| VIRP.PA | VIRBAC SA | 20.76 | 3.02B | ||
| DMP.DE | DERMAPHARM HOLDING SE | 17.51 | 2.03B |
Recordati SpA engages in the research, development, manufacture, and marketing of pharmaceuticals. The company is headquartered in Milan, Milano and currently employs 4,583 full-time employees. The company promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The firm is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. The company operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The firm owns and operates through Natural Point srl also in the food supplement sector.
RECORDATI INDUSTRIA CHIMICA
Via Matteo Civitali, 1
Milan MILANO IT
Employees: 4539
Phone: 3902487871
Recordati SpA engages in the research, development, manufacture, and marketing of pharmaceuticals. The company is headquartered in Milan, Milano and currently employs 4,583 full-time employees. The company promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The firm is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. The company operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The firm owns and operates through Natural Point srl also in the food supplement sector.
The current stock price of REC.MI is 48.26 EUR. The price decreased by -0.25% in the last trading session.
RECORDATI INDUSTRIA CHIMICA (REC.MI) has a dividend yield of 2.58%. The yearly dividend amount is currently 1.23.
REC.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
REC.MI stock is listed on the Euronext Milan exchange.
RECORDATI INDUSTRIA CHIMICA (REC.MI) operates in the Health Care sector and the Pharmaceuticals industry.
You can find the ownership structure of RECORDATI INDUSTRIA CHIMICA (REC.MI) on the Ownership tab.